A total of 40 patients with relapsed/refractory Hodgkin's disease (HD) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) from an HLA-identical sibling (n = 20) or a matched unrelated donor (n = 20). The median age was 31 years (range 18-58). Disease status at allo-SCT was refractory relapse (n = 14) or sensitive relapse (n = 26). The conditioning regimens were fludarabinelcyclophosphamide ± autithymocyte globulin (n =14), a less intensive regimen, and fludarabine-melphalan (FM) (n = 26), a more intensive one. The two groups had similar prognostic factors. The median time to neutrophil recovery (ie absolute neutrophil count ≥ 500/μl) was 12 days (range 10-24). The median time to platelet recovery (ie platelet count ≥ 20 000/μl) was 17 days (range 7-132). Day 100 and cumulative (18-month) transplant-related mortalities (TRMs) were 5 and 22%. Twenty-four patients (60%) are alive (14 in complete remission or complete remission, unconfirmed/uncertain) with a median follow-up of 13 mouths (4-78). In all, 16 patients expired (TRM n = 8, disease progression n = 8). FM patients had better overall survival (73 vs 39% at 18 months; P = 0.03), and a trend towards better progression-free survival (37 vs 21% at 18 months; P = 0.2). RIC allo-SCT is feasible in relapsed/refractory HD patients with a low TRM. The intensity of the preparative regimen affects survival.
- Allogeneic stem cell transplantation
- Bone marrow transplantation
- Hodgkin's disease
- Hodgkin's lymphoma
- Peripheral blood stem cell transplantation
ASJC Scopus subject areas